DOCSLIB.ORG

Autosomal-Recessive Cerebellar Ataxia Caused by a Novel ADCK3

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Autosomal-Recessive Cerebellar Ataxia Caused by a Novel ADCK3 J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2013-306483 on 11 November 2013. Downloaded from Neurogenetics RESEARCH PAPER Autosomal-recessive cerebellar ataxia caused by a novel ADCK3 mutation that elongates the protein: clinical, genetic and biochemical characterisation Yo-Tsen Liu,1,2,3,4 Joshua Hersheson,2 Vincent Plagnol,5 Katherine Fawcett,2 Kate E C Duberley,2 Elisavet Preza,2 Iain P Hargreaves,6 Annapurna Chalasani,6 Open Access 1,2 2 1,2 1,2 Scan to access more Matilde Laurá, Nick W Wood, Mary M Reilly, Henry Houlden free content ▸ Additional material is ABSTRACT potentially treatable causes of ARCA as the symp- published online only. To view Background The autosomal-recessive cerebellar ataxias toms in many patients improve with CoQ10 sup- please visit the journal online 45 (http://dx.doi.org/10.1136/ (ARCA) are a clinically and genetically heterogeneous plementation. CoQ10 is a lipid-soluble jnnp-2013-306483). group of neurodegenerative disorders. The large number component located in the inner mitochondrial of ARCA genes leads to delay and difficulties obtaining membrane. It plays a pivotal role in the oxidative 1MRC Centre for Neuromuscular Diseases, an exact diagnosis in many patients and families. phosphorylation system (OXPHOS) by shuttling UCL Institute of Neurology Ubiquinone (CoQ10) deficiency is one of the potentially electrons derived from mitochondrial respiratory and National Hospital for treatable causes of ARCAs as some patients respond to chain (MRC) complexes I (NADH ubiquinone Neurology and Neurosurgery, CoQ10 supplementation. The AarF domain containing oxidoreductase) and II (succinate ubiquinone oxi- London, UK 2Department of Molecular kinase 3 gene (ADCK3) is one of several genes doreductase) to complex III (ubiquinol cytochrome Neuroscience, UCL Institute of associated with CoQ10 deficiency. ADCK3 encodes a c oxidoreductase), and also participates in other Neurology and National mitochondrial protein which functions as an electron- cellular processes as a potent antioxidant, and by Hospital for Neurology and transfer membrane protein complex in the mitochondrial influencing pyrimidine metabolism.67 Neurosurgery, London, UK respiratory chain (MRC). The AarF domain containing kinase 3 gene 3Section of Epilepsy, Methods We report two siblings from a consanguineous (ADCK3, MIM_606980) is one of the genes Department of Neurology, copyright. Neurological Institute, Taipei Pakistani family who presented with cerebellar ataxia and involved in the biosynthetic pathway of CoQ10, Veterans General Hospital, severe myoclonus from adolescence. Whole exome thus, their mutations can cause CoQ10 deficiency Taipei, Taiwan fi 4 sequencing and biochemical assessment of broblasts where most mutations are at loss of function. National Yang-Ming University ADCK3 School of Medicine, Taipei, were performed in the index patient. is the homologue of the yeast Coq8 gene Taiwan Results A novel homozygous frameshift mutation in and encodes a mitochondrial protein which func- 5University College London, ADCK3 (p.Ser616Leufs*114), was identified in both tions in an electron-transferring membrane protein Genetics Institute, London, UK 8 ADCK3 6 siblings. This frameshift mutation results in the loss of complex in the MRC. Patients with muta- Neurometabolic Unit, National the stop codon, extending the coding protein by 81 tions usually have disease onset in infancy or early Hospital of Neurology and fi fi Neurosurgery, London, UK amino acids. Signi cant CoQ10 de ciency and reduced childhood and can present with pure cerebellar MRC enzyme activities in the index patient's fibroblasts ataxia or a complex phenotype with additional fea- Correspondence to suggested that the mutant protein may reduce the tures, such as seizures, cognitive impairment, Professor Henry Houlden, efficiency of mitochondrial electron transfer. CoQ10 depression, peripheral neuropathy, strabismus or http://jnnp.bmj.com/ Department of Molecular 8–11 Neuroscience and MRC Centre supplementation was initiated following these genetic exercise intolerance. for Neuromuscular Diseases, and biochemical analyses. She gained substantial In this study, we report two affected siblings in UCL Institute of Neurology and improvement in myoclonic movements, ataxic gait and their 20 s, from a consanguineous family of National Hospital for dysarthric speech after treatment. Pakistani origin, who both presented with cerebel- Neurology and Neurosurgery, Conclusion This study highlights the importance of lar ataxia, myoclonus and dysarthria. Whole exome Queen Square House, Queen fi Square, London WC1N 3BG, diagnosing ADCK3 mutations and the potential bene t sequencing (WES) performed in the index patient UK; [email protected] of treatment for patients. The identification of this new identified a homozygous frameshift mutation in on September 26, 2021 by guest. Protected mutation broadens the phenotypic spectrum associated ADCK3. This mutation results in the loss of the Received 8 August 2013 with ADCK3 mutations and provides further stop codon and extension of the protein by 81 Revised 7 October 2013 Accepted 14 October 2013 understanding of their pathogenic mechanism. amino acids. CoQ10 level and the MRC enzyme Published Online First activities in the index patient’s fibroblasts were also 11 November 2013 investigated and CoQ10 supplementation was given to her based on the genetic and functional results. INTRODUCTION Significant improvements in all symptoms men- Autosomal-recessive cerebellar ataxias (ARCA) are tioned above were observed after treatment. a group of inherited neurodegenerative disorders characterised primarily by cerebellar ataxia, but are frequently associated with other neurological mani- PATIENTS AND METHODS festations including spasticity, peripheral neur- Patients To cite: Liu Y-T, Hersheson J, Plagnol V, opathy, seizures and optic atrophy. ARCAs are With informed consent, we clinically evaluated and et al. J Neurol Neurosurg genetically heterogeneous with more than 20 causa- obtained blood samples from the index patient and – Psychiatry 2014;85: tive genes currently recognised.1 3 Coenzyme Q10 the affected sibling. A skin biopsy was also obtained – 493 498. (CoQ10) deficiency (MIM_607426) is one of the from the index patient. This study was approved by Liu Y-T, et al. J Neurol Neurosurg Psychiatry 2014;85:493–498. doi:10.1136/jnnp-2013-306483 493 J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2013-306483 on 11 November 2013. Downloaded from Neurogenetics the joint ethics committee of UCL Institute of Neurology and The C4 (150 mm×3 mm, 3 mm) with a Gold C4 guard column (3, National Hospital for Neurology and Neurosurgery, London, UK. 10 mm length, 3 mm) operated at 40°C at a flow rate of 0.4 mL/ min. The mobile phases consisted of methanol, 4 mM ammo- WES and variant calling nium acetate 0.1% formic acid and methanol:isopropanol:formic In an attempt to rapidly identify the underlying genetic muta- acid (45:55:0.5, v/v/v) containing 5 mM methylamine as an ion tion, WES was carried out on the index patient at the NIH pair reagent. Isocratic delivery of the mobile phase ensured (Bethesda, USA). Nimblegen SeqCap EZ Exome kit (in solution elution of the CoQ10 methylammonium adduct at approximately capture) was used for the exome capture. Shotgun sequencing 8 min. D6-CoQ10 was used as an internal standard. libraries were generated from 3 mg genomic DNA which was extracted from peripheral blood using Flexigene extraction kit MRC enzyme activities and Autopure LS (Qiagen) extraction system. Sequencing was Activities of MRC complex I, complex II–III, complex IV (cyto- performed on a Genome Analyzer IIx, according to the manu- chrome c oxidase) and citrate synthase (CS) were determined in facturer’’s instruction. FASTQ files were aligned to the hg19 ref- the fibroblast cells according to methods previously described.13 erence sequence using Novoalign V.2.07.19, including hard and Results were expressed as a ratio to CS activity and were nor- soft clipping, quality calibration and adapter trimming. malised against protein. Protein quantification was determined Duplicate reads were excluded using the PICARD tool using the Lowry method using bovine serum albumin as a MarkDuplicates. Calling was performed using SAMtools V.0.18 standard.14 and single sample calling. The resulting calls were annotated with ANNOVAR. Candidate variants were filtered based on RESULTS function: frameshift, premature stop, non-synonymous or Clinical features potential splice-altering variants (defined as being within 5 bp of This 35-year-old lady started to experience myoclonus and jerky the actual splice site) and frequency (<0.5% in the 1000 tremor in the head and limbs at 10 years old. Slurred speech Genomes and the National Heart, Lung, and Blood Institute and unsteady gait developed subsequently in her second decade. (NHLBI) Exome Sequencing Project database (http://evs.gs. There was no response to levodopa. By 30 years of age, she had washington.edu/EVS/) for homozygous and compound hetero- become wheelchair-dependent because of the ataxic myoclonic zygous variants, and absent from both of these databases for gait. She also had difficulty in writing and holding objects due heterozygous variants). VCF tools were used to annotate gene to ataxia and involuntary movements. Her speech fatigued information for the remaining novel variants. The Integrative easily, was often tremulous and dysarthric and she also com- Genomics Viewer (IGV) was used to inspect variants. plained of
Load more

Recommended publications
  • The Landscape of Human Mutually Exclusive Splicing
    bioRxiv preprint doi: https://doi.org/10.1101/133215; this version posted May 2, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. The landscape of human mutually exclusive splicing Klas Hatje1,2,#,*, Ramon O. Vidal2,*, Raza-Ur Rahman2, Dominic Simm1,3, Björn Hammesfahr1,$, Orr Shomroni2, Stefan Bonn2§ & Martin Kollmar1§ 1 Group of Systems Biology of Motor Proteins, Department of NMR-based Structural Biology, Max-Planck-Institute for Biophysical Chemistry, Göttingen, Germany 2 Group of Computational Systems Biology, German Center for Neurodegenerative Diseases, Göttingen, Germany 3 Theoretical Computer Science and Algorithmic Methods, Institute of Computer Science, Georg-August-University Göttingen, Germany § Corresponding authors # Current address: Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland $ Current address: Research and Development - Data Management (RD-DM), KWS SAAT SE, Einbeck, Germany * These authors contributed equally E-mail addresses: KH: [email protected], RV: [email protected], RR: [email protected], DS: [email protected], BH: [email protected], OS: [email protected], SB: [email protected], MK: [email protected] - 1 - bioRxiv preprint doi: https://doi.org/10.1101/133215; this version posted May 2, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Downloaded from the App Store and Nucleobase, Nucleotide and Nucleic Acid Metabolism 7 Google Play
    Hoytema van Konijnenburg et al. Orphanet J Rare Dis (2021) 16:170 https://doi.org/10.1186/s13023-021-01727-2 REVIEW Open Access Treatable inherited metabolic disorders causing intellectual disability: 2021 review and digital app Eva M. M. Hoytema van Konijnenburg1†, Saskia B. Wortmann2,3,4†, Marina J. Koelewijn2, Laura A. Tseng1,4, Roderick Houben6, Sylvia Stöckler‑Ipsiroglu5, Carlos R. Ferreira7 and Clara D. M. van Karnebeek1,2,4,8* Abstract Background: The Treatable ID App was created in 2012 as digital tool to improve early recognition and intervention for treatable inherited metabolic disorders (IMDs) presenting with global developmental delay and intellectual disabil‑ ity (collectively ‘treatable IDs’). Our aim is to update the 2012 review on treatable IDs and App to capture the advances made in the identifcation of new IMDs along with increased pathophysiological insights catalyzing therapeutic development and implementation. Methods: Two independent reviewers queried PubMed, OMIM and Orphanet databases to reassess all previously included disorders and therapies and to identify all reports on Treatable IDs published between 2012 and 2021. These were included if listed in the International Classifcation of IMDs (ICIMD) and presenting with ID as a major feature, and if published evidence for a therapeutic intervention improving ID primary and/or secondary outcomes is avail‑ able. Data on clinical symptoms, diagnostic testing, treatment strategies, efects on outcomes, and evidence levels were extracted and evaluated by the reviewers and external experts. The generated knowledge was translated into a diagnostic algorithm and updated version of the App with novel features. Results: Our review identifed 116 treatable IDs (139 genes), of which 44 newly identifed, belonging to 17 ICIMD categories.
    [Show full text]
  • ADCK3 Protein Recombinant Human Protein Expressed in Sf9 Cells
    Catalog # Aliquot Size A37-11G-20 20 µg A37-11G-50 50 µg ADCK3 Protein Recombinant human protein expressed in Sf9 cells Catalog # A37-11G Lot # Z1457 -3 Product Description Purity Recombinant human ADCK3 (156-end) was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag. This gene accession number is NM_020247 . The purity of ADCK3 protein was Gene Aliases determined to be >75% by densitometry. ARCA2; CABC1; COQ10D4; COQ8; SCAR9 Approx. MW 83 kDa . Formulation Recombinant protein stored in 50mM Tris-HCl, pH 7.5, 50mM NaCl, 10mM glutathione, 0.1mM EDTA, 0.25mM DTT, 0.1mM PMSF, 25% glycerol. Storage and Stability Store product at –70 oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles. Scientific Background ADCK3 or aarF domain containing kinase 3 is a mitochondrial protein similar to yeast ABC1, which functions in an electron-transferring membrane protein complex in the respiratory chain. ADCK3 is involved in coenzyme Q10 synthesis which is essential for proper functioning of the mitochondrial respiratory chain (1). ADCK3 Protein Expression of ADCK3 is induced by the tumor suppressor Recombinant human protein expressed in Sf9 cells p53 and in response to DNA damage, and inhibiting its expression partially suppresses p53-induced apoptosis (2). Catalog # A37-11G Lot # Z1457-3 References Purity >75% Concentration 0.1 µ g/ µl 1. Lagier-Tourenne, C. et.al: ADCK3, an ancestral kinase, is Stability 1yr at –70 oC from date of shipment mutated in a form of recessive ataxia associated with Storage & Shipping Store product at –70 oC.
    [Show full text]
  • Human Mitochondrial Pathologies of the Respiratory Chain and ATP Synthase: Contributions from Studies of Saccharomyces Cerevisiae
    life Review Human Mitochondrial Pathologies of the Respiratory Chain and ATP Synthase: Contributions from Studies of Saccharomyces cerevisiae Leticia V. R. Franco 1,2,* , Luca Bremner 1 and Mario H. Barros 2 1 Department of Biological Sciences, Columbia University, New York, NY 10027, USA; [email protected] 2 Department of Microbiology,Institute of Biomedical Sciences, Universidade de Sao Paulo, Sao Paulo 05508-900, Brazil; [email protected] * Correspondence: [email protected] Received: 27 October 2020; Accepted: 19 November 2020; Published: 23 November 2020 Abstract: The ease with which the unicellular yeast Saccharomyces cerevisiae can be manipulated genetically and biochemically has established this organism as a good model for the study of human mitochondrial diseases. The combined use of biochemical and molecular genetic tools has been instrumental in elucidating the functions of numerous yeast nuclear gene products with human homologs that affect a large number of metabolic and biological processes, including those housed in mitochondria. These include structural and catalytic subunits of enzymes and protein factors that impinge on the biogenesis of the respiratory chain. This article will review what is currently known about the genetics and clinical phenotypes of mitochondrial diseases of the respiratory chain and ATP synthase, with special emphasis on the contribution of information gained from pet mutants with mutations in nuclear genes that impair mitochondrial respiration. Our intent is to provide the yeast mitochondrial specialist with basic knowledge of human mitochondrial pathologies and the human specialist with information on how genes that directly and indirectly affect respiration were identified and characterized in yeast. Keywords: mitochondrial diseases; respiratory chain; yeast; Saccharomyces cerevisiae; pet mutants 1.
    [Show full text]
  • Functional Characterization of Human Adck3 and Adck4, Mitochondrial Atypical Kinases
    FUNCTIONAL CHARACTERIZATION OF HUMAN ADCK3 AND ADCK4, MITOCHONDRIAL ATYPICAL KINASES by Brody Wheeler A thesis submitted to the Department of Biomedical and Molecular Sciences In conformity with the requirements for the degree of Master of Science Queen’s University Kingston, Ontario, Canada November, 2015 Copyright © Brody Wheeler, 2015 Abstract AarF domain containing kinases 3 and 4 (ADCK3 and ADCK4, respectively) are paralogous human mitochondrial proteins, co-orthologs of the yeast protein Coq8 and bacterial protein UbiB. These proteins are required in the biosynthesis of coenzyme Q, a lipid-soluble electron carrier well known for its role in energy metabolism, more specifically in the electron transport chain. Patients with mutations in ADCK3 experience an onset of neurological disorders from childhood, including cerebellar ataxia and exercise intolerance. Mutations in ADCK4 cause steroid-resistant nephrotic syndrome, and are also associated with coenzyme Q deficiency. Aside from this minimal characterization at the biochemical level, the precise biological functions of both ADCK3 and ADCK4 remain poorly understood. After extensive screening for soluble recombinant protein expression, N-terminal fusions with maltose-binding protein were found to facilitate the overexpression of human ADCK3 and ADCK4 truncations in Escherichia coli as soluble and biologically active entities. For the first time, our work revealed Mg2+-dependent ATPase activity of ADCK3, providing strong support for the theoretical prediction of these proteins being functional atypical kinases. Subsequent experimentation confirmed protein kinase activity for both ADCK3 and ADCK4. This observed kinase activity was inhibited by the presence of an atypical N-terminal extension – containing an invariant KxGQ motif – found within the kinase domains of these proteins, suggesting an autoinhibitory role for this motif.
    [Show full text]
  • Supplementary Information Contents
    Supplementary Information Contents Supplementary Methods: Additional methods descriptions Supplementary Results: Biology of suicidality-associated loci Supplementary Figures Supplementary Figure 1: Flow chart of UK Biobank participants available for primary analyses (Ordinal GWAS and PRS analysis) Supplementary Figure 2: Flow chart of UK Biobank participants available for secondary analyses. The flow chart of participants is the same as Supplementary Figure 1 up to the highlighted box. Relatedness exclusions were applied for A) the DSH GWAS considering the categories Controls, Contemplated self-harm and Actual self-ham and B) the SIA GWAS considering the categories Controls, Suicidal ideation and attempted suicide. Supplementary Figure 3: Manhattan plot of GWAS of ordinal DSH in UK Biobank (N=100 234). Dashed red line = genome wide significance threshold (p<5x10-5). Inset: QQ plot for genome-wide association with DSH. Red line = theoretical distribution under the null hypothesis of no association. Supplementary Figure 4: Manhattan plot of GWAS of ordinal SIA in UK Biobank (N=108 090). Dashed red line = genome wide significance threshold (p<5x10-5). Inset: QQ plot for genome-wide association with SIA. Red line = theoretical distribution under the null hypothesis of no association. Supplementary Figure 5: Manhattan plot of gene-based GWAS of ordinal suicide in UK Biobank (N=122 935). Dashed red line = genome wide significance threshold (p<5x10-5). Inset: QQ plot for genome-wide association with suicidality in UK Biobank. Red line = theoretical distribution under the null hypothesis of no association. Supplementary Figure 6: Manhattan plot of gene-based GWAS of ordinal DSH in UK Biobank (N=100 234).
    [Show full text]
  • COQ8A Gene Coenzyme Q8A
    COQ8A gene coenzyme Q8A Normal Function The COQ8A gene provides instructions for making a protein that is involved in the production of a molecule called coenzyme Q10, which has several critical functions in cells throughout the body. In cell structures called mitochondria, coenzyme Q10 plays an essential role in a process called oxidative phosphorylation, which converts the energy from food into a form cells can use. Coenzyme Q10 is also involved in producing pyrimidines, which are building blocks of DNA, its chemical cousin RNA, and molecules such as ATP and GTP that serve as energy sources in the cell. In cell membranes, coenzyme Q10 acts as an antioxidant, protecting cells from damage caused by unstable oxygen-containing molecules (free radicals), which are byproducts of energy production. Health Conditions Related to Genetic Changes Primary coenzyme Q10 deficiency At least 36 mutations in the COQ8A gene have been found to cause a disorder known as primary coenzyme Q10 deficiency. This rare disease usually becomes apparent in infancy or early childhood, but it can occur at any age. It can affect many parts of the body, most often the brain, muscles, and kidneys. The COQ8A gene mutations associated with this disorder change the structure of the COQ8A protein or prevent its production, which impairs the normal production of coenzyme Q10. Studies suggest that a shortage (deficiency) of coenzyme Q10 impairs oxidative phosphorylation and increases the vulnerability of cells to damage from free radicals. A deficiency of coenzyme Q10 may also disrupt the production of pyrimidines. These changes can cause cells throughout the body to malfunction, which may help explain the variety of organs and tissues that can be affected by primary coenzyme Q10 deficiency.
    [Show full text]
  • Disorders of Human Coenzyme Q10 Metabolism: an Overview
    International Journal of Molecular Sciences Review Disorders of Human Coenzyme Q10 Metabolism: An Overview Iain Hargreaves 1,*, Robert A. Heaton 1 and David Mantle 2 1 School of Pharmacy, Liverpool John Moores University, L3 5UA Liverpool, UK; [email protected] 2 Pharma Nord (UK) Ltd., Telford Court, Morpeth, NE61 2DB Northumberland, UK; [email protected] * Correspondence: [email protected] Received: 19 August 2020; Accepted: 11 September 2020; Published: 13 September 2020 Abstract: Coenzyme Q10 (CoQ10) has a number of vital functions in all cells, both mitochondrial and extramitochondrial. In addition to its key role in mitochondrial oxidative phosphorylation, CoQ10 serves as a lipid soluble antioxidant, plays an important role in fatty acid, pyrimidine and lysosomal metabolism, as well as directly mediating the expression of a number of genes, including those involved in inflammation. In view of the central role of CoQ10 in cellular metabolism, it is unsurprising that a CoQ10 deficiency is linked to the pathogenesis of a range of disorders. CoQ10 deficiency is broadly classified into primary or secondary deficiencies. Primary deficiencies result from genetic defects in the multi-step biochemical pathway of CoQ10 synthesis, whereas secondary deficiencies can occur as result of other diseases or certain pharmacotherapies. In this article we have reviewed the clinical consequences of primary and secondary CoQ10 deficiencies, as well as providing some examples of the successful use of CoQ10 supplementation in the treatment of disease. Keywords: coenzyme Q10; mitochondria; oxidative stress; antioxidant; deficiencies 1. Introduction Coenzyme Q10 (CoQ10) is a lipid-soluble molecule comprising a central benzoquinone moiety, to which is attached a 10-unit polyisoprenoid lipid tail [1] (Figure1).
    [Show full text]
  • ARTICLE ADCK3, an Ancestral Kinase, Is Mutated in a Form Of
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector ARTICLE ADCK3, an Ancestral Kinase, Is Mutated in a Form of Recessive Ataxia Associated with Coenzyme Q10 Deficiency Clotilde Lagier-Tourenne,1 Meriem Tazir,2 Luis Carlos Lo´pez,3 Catarina M. Quinzii,3 Mirna Assoum,1 Nathalie Drouot,1 Cleverson Busso,4 Samira Makri,5 Lamia Ali-Pacha,2 Traki Benhassine,6 Mathieu Anheim,1,7 David R. Lynch,8 Christelle Thibault,1 Fre´de´ric Plewniak,1 Laurent Bianchetti,1 Christine Tranchant,7 Olivier Poch,1 Salvatore DiMauro,3 Jean-Louis Mandel,1 Mario H. Barros,4 Michio Hirano,3 and Michel Koenig1,* Muscle coenzyme Q10 (CoQ10 or ubiquinone) deficiency has been identified in more than 20 patients with presumed autosomal-reces- sive ataxia. However, mutations in genes required for CoQ10 biosynthetic pathway have been identified only in patients with infantile- onset multisystemic diseases or isolated nephropathy. Our SNP-based genome-wide scan in a large consanguineous family revealed a locus for autosomal-recessive ataxia at chromosome 1q41. The causative mutation is a homozygous splice-site mutation in the aarF-do- main-containing kinase 3 gene (ADCK3). Five additional mutations in ADCK3 were found in three patients with sporadic ataxia, includ- ing one known to have CoQ10 deficiency in muscle. All of the patients have childhood-onset cerebellar ataxia with slow progression, and three of six have mildly elevated lactate levels. ADCK3 is a mitochondrial protein homologous to the yeast COQ8 and the bacterial UbiB proteins, which are required for CoQ biosynthesis.
    [Show full text]
  • ADCK4-Associated Glomerulopathy Causes Adolescence-Onset FSGS
    BRIEF COMMUNICATION www.jasn.org ADCK4-Associated Glomerulopathy Causes Adolescence-Onset FSGS †‡ | | Emine Korkmaz,* Beata S. Lipska-Zie˛ tkiewicz, Olivia Boyer,§ ¶ Olivier Gribouval,§ † †† ‡‡ Cecile Fourrage,** Mansoureh Tabatabaei, Sven Schnaidt, Safak Gucer, Figen Kaymaz,§§ || ††† ‡‡‡ Mustafa Arici, Ayhan Dinckan,¶¶ Sevgi Mir,*** Aysun K. Bayazit, Sevinc Emre, ||| ||| Ayse Balat,§§§ Lesley Rees, Rukshana Shroff, Carsten Bergmann,¶¶¶ Chebl Mourani,**** |†††† ‡‡‡‡ † Corinne Antignac,§ Fatih Ozaltin,* §§§§ Franz Schaefer, and the PodoNet Consortium BRIEF COMMUNICATION *Nephrogenetics Laboratory, Department of Pediatric Nephrology, Hacettepe University Faculty of Medicine, Ankara, Turkey; †Division of Pediatric Nephrology, Center for Pediatrics and Adolescent Medicine, Heidelberg, Germany; ‡Department of Biology and Genetics, Medical University of Gdansk, Gdansk, Poland; §Institut National de la Santé et de la Recherche Médicale (INSERM) Unité mixte de recherche (UMR) U1163, Laboratory of Hereditary Kidney Diseases, Paris, France; |Université Paris Descartes, Sorbonne Paris Cité, Imagine Institute, Paris, France; ¶Department of Pediatric Nephrology, Necker Hospital, Assistance Publique– Hôpitaux de Paris, Paris, France; **Paris Descartes University Bioinformatics Platform, Imagine Institute, Paris, France; ††Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany; Departments of ‡‡Pediatric Pathology, §§Histology and Embryology, and ||Nephrology, Hacettepe University Faculty of Medicine, Ankara, Turkey;
    [Show full text]
  • Mitochondrial Function and Lifespan of Mice with Controlled Ubiquinone Biosynthesis
    ARTICLE Received 28 Jul 2014 | Accepted 26 Jan 2015 | Published 6 Mar 2015 DOI: 10.1038/ncomms7393 Mitochondrial function and lifespan of mice with controlled ubiquinone biosynthesis Ying Wang1, Daniella Oxer1 & Siegfried Hekimi1 Ubiquinone (UQ) is implicated in mitochondrial electron transport, superoxide generation and as a membrane antioxidant. Here we present a mouse model in which UQ biosynthesis can be interrupted and partially restored at will. Global loss of UQ leads to gradual loss of mitochondrial function, gradual development of disease phenotypes and shortened lifespan. However, we find that UQ does not act as antioxidant in vivo and that its requirement for electron transport is much lower than anticipated, even in vital mitochondria-rich organs. In fact, severely depressed mitochondrial function due to UQ depletion in the heart does not acutely impair organ function. In addition, we demonstrate that severe disease phenotypes and shortened lifespan are reversible upon partial restoration of UQ levels and mitochondrial function. This observation strongly suggests that the irreversible degenerative phenotypes that characterize ageing are not secondarily caused by the gradual mitochondrial dysfunction that is observed in aged animals. 1 Department of Biology, McGill University, Montreal, Quebec, Canada H3A 1B1. Correspondence and requests for materials should be addressed to S.H. (email: [email protected]). NATURE COMMUNICATIONS | 6:6393 | DOI: 10.1038/ncomms7393 | www.nature.com/naturecommunications 1 & 2015 Macmillan Publishers Limited. All rights reserved. ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7393 biquinone (UQ), also known as coenzyme Q (CoQ), is a redox-active lipophilic molecule that is found in all cells COOH COOH Uand in the membranes of many organelles where it OH participates in a variety of cellular processes1.
    [Show full text]
  • Cell-Type–Specific Eqtl of Primary Melanocytes Facilitates Identification of Melanoma Susceptibility Genes
    Downloaded from genome.cshlp.org on September 26, 2021 - Published by Cold Spring Harbor Laboratory Press Research Cell-type–specific eQTL of primary melanocytes facilitates identification of melanoma susceptibility genes Tongwu Zhang,1,7 Jiyeon Choi,1,7 Michael A. Kovacs,1 Jianxin Shi,2 Mai Xu,1 NISC Comparative Sequencing Program,9 Melanoma Meta-Analysis Consortium,10 Alisa M. Goldstein,3 Adam J. Trower,4 D. Timothy Bishop,4 Mark M. Iles,4 David L. Duffy,5 Stuart MacGregor,5 Laufey T. Amundadottir,1 Matthew H. Law,5 Stacie K. Loftus,6 William J. Pavan,6,8 and Kevin M. Brown1,8 1Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA; 2Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA; 3Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA; 4Section of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, LS9 7TF, United Kingdom; 5Statistical Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, 4006, Australia; 6Genetic Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892, USA Most expression quantitative trait locus (eQTL) studies to date have been performed in heterogeneous tissues as opposed to specific cell types. To better understand the cell-type–specific regulatory landscape of human melanocytes, which give rise to melanoma but account for <5% of typical human skin biopsies, we performed an eQTL analysis in primary melanocyte cul- tures from 106 newborn males.
    [Show full text]